Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids

NCT: NCT02386137 · COMPLETED

NCT IDNCT02386137
StatusCOMPLETED
Start Date2015-07-22
Completion2017-10-31

Brief Summary

Magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU) ablation is increasingly being used worldwide to treat symptomatic uterine fibroids because of its excellent therapeutic efficacy in controlling symptoms and its excellent safety record. Despite the benefits, it should be recognized that MR HIFU ablation does not always yield good therapeutic outcomes. High signal intensity on T2-weighted MR images and a high volume transfer constant (or Ktrans) on dynamic contrast material-enhanced MR images are the most well-known risk factors for poor ablation outcomes as measured with the non-perfused volume (NPV) ratio (ie, NPV divided by fibroid volume). The aim of this study is to assess the influence of fibroid perfusion (evaluated by MRI and contrast enhanced ultrasound), apparent diffusion coefficient (evaluated by MR-diffusion imaging) and fibroid stiffness (evaluated by ARFI) on ablation efficiency during uterine fibroid treatment by MR-HIFU.

Frequently Asked Questions

What is Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids?

Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids is a clinical trial registered under NCT02386137. Current status: COMPLETED.

What is the status of NCT02386137?

The current status of NCT02386137 (Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids) is: COMPLETED.

When did Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids start?

Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids started on 2015-07-22.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.